NCT07362186

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

A Phase III, Open-Label, Multicenter, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of LM-108 in Combination With Toripalimab Versus Paclitaxel Injection as Second-Line Therapy for CCR8-Positive Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: LaNova Medicines Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.

Conditions

• Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

Interventions

Type	Name	Description
DRUG	LM-108 in combination with Toripalimab	LM-108 combined with Toripalimab administered intravenously on Day 1 every 3 weeks
DRUG	Paclitaxel injection intravenous infusion	Paclitaxel injection administered at a dose of 80 mg/m² on Day 1, 8, and 15 every 4 weeks

Timeline

• Start date: 2026-04-03
• Primary completion: 2028-08-17
• Completion: 2028-09-28
• First posted: 2026-01-23
• Last updated: 2026-01-23

Locations

1 site across 1 country: China